title: Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome.
abstract: OBJECTIVE
  To characterize the clinical course of myopathy associated with antibodies to signal recognition particle (SRP), or anti-SRP myopathy.
  
  
  METHODS
  Case series.
  
  
  METHODS
  Keio University Hospitals and National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
  
  
  METHODS
  We reviewed clinical features of 27 patients with anti-SRP myopathy and analyzed disease progression and neurological outcome.
  
  
  METHODS
  Anti-SRP antibodies in serum were detected by RNA immunoprecipitation assay using extracts of K562 cells.
  
  
  RESULTS
  Of the 27 patients, 5 (19%) showed chronic progressive muscle weakness as well as atrophy of limbs and trunk muscles from a younger age with more severe neurological outcomes compared with the other 22 patients(81%) with the subacute form.
  
  
  CONCLUSIONS
  A subset of patients with anti-SRP myopathy can show a chronic progressive form associated with severe clinical deficits.
authors.affiliation: Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. sgsuzuki@z3.keio.jp
authors.forename: Shigeaki
authors.initials: S
authors.lastname: Suzuki
authors.forename: Yukiko K
authors.initials: YK
authors.lastname: Hayashi
authors.forename: Masataka
authors.initials: M
authors.lastname: Kuwana
authors.forename: Rie
authors.initials: R
authors.lastname: Tsuburaya
authors.forename: Norihiro
authors.initials: N
authors.lastname: Suzuki
authors.forename: Ichizo
authors.initials: I
authors.lastname: Nishino
mesh_terms: D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood*; D003402:Creatine Kinase / Q000097:blood; D018450:Disease Progression; D005260:Female; D006801:Humans; D047468:Immunoprecipitation; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D009422:Nervous System Diseases / Q000209:etiology*; D011239:Prednisolone / Q000627:therapeutic use; D012720:Severity of Illness Index; D018271:Signal Recognition Particle / Q000276:immunology*; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D001323:Autoantibodies; D018271:Signal Recognition Particle; D011239:Prednisolone; D003402:Creatine Kinase